0001567619-19-014141.txt : 20190701 0001567619-19-014141.hdr.sgml : 20190701 20190701103759 ACCESSION NUMBER: 0001567619-19-014141 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b ITEM INFORMATION: Section 3(c)(7) FILED AS OF DATE: 20190701 DATE AS OF CHANGE: 20190701 EFFECTIVENESS DATE: 20190701 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MPM ONCOLOGY INNOVATIONS FUND LP CENTRAL INDEX KEY: 0001719960 IRS NUMBER: 821760795 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-315855 FILM NUMBER: 19931817 BUSINESS ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-425-9200 MAIL ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: MPM ONCOLOGY INNOVATIONS FUND L.P. DATE OF NAME CHANGE: 20171017 D/A 1 primary_doc.xml X0708 D/A LIVE 0001719960 MPM ONCOLOGY INNOVATIONS FUND LP 450 KENDALL STREET CAMBRIDGE MA MASSACHUSETTS 02142 617-425-9200 DELAWARE None MPM ONCOLOGY INNOVATIONS FUND L.P. Limited Partnership true 2017 N/A MPM Oncology Innovations Fund GP LLC 450 Kendall Street Cambridge MA MASSACHUSETTS 02142 Executive Officer Promoter The General Partner of the Issuer. Ansbert Gadicke c/o MPM Oncology Innovations Fund LP 450 Kendall Street Cambridge MA MASSACHUSETTS 02142 Executive Officer Promoter Dr. Gadicke is the Manager of the General Partner of the Issuer. Luke Evnin c/o MPM Oncology Innovations Fund LP 450 Kendall Street Cambridge MA MASSACHUSETTS 02142 Executive Officer Promoter Dr. Evnin is the Manager of the General Partner of the Issuer. Pooled Investment Fund Venture Capital Fund false Decline to Disclose 06b 3C.7 true 0001140361-18-030740 2018-07-12 true true true Limited Partnership Interests. The General Partner may waive the minimum capital commitment of $250,000 in its sole discretion. false 0 None None UBS Financial Services Inc. 8174 1285 Avenue of the Americas New York NY NEW YORK 10019 All States false 200000000 52650002 147349998 false 31 0 true 0 The persons listed in Item 12 will be paid a fee of 2% of an investor's aggregate investment that are clients of such persons. The fee will be paid by the investors and not by the Issuer. The amount of such fee is not known. 0 true Certain persons named in Item 3 or affiliate(s) thereof may receive payments deemed to be made from the proceeds of the offering, including management fees. The amount of such payments cannot be estimated at this time. false MPM ONCOLOGY INNOVATIONS FUND LP /s/ Ansbert Gadicke Ansbert Gadicke Manager of the General Partner of the Issuer 2019-06-28